FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: nymox pharmaceutical

Sort
E.g., 2013-05-25
E.g., 2013-05-25
Enter a comma separated list of user names.

Recordati and Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced recently the signing of a European licensing agreement for the development and commercialization of NX-1207, Nymox's Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH).

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

ADVERTISE WITH US